The Development of Oral Nalbuphine Dosage Form

NCT00924079 | Unknown DMC

• 2 other identifiers: NAL001TSGHIRB096-02-010-I
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate possible responses to pharmacokinetic properties for nalbuphine oral formulations in healthy volunteers.

Conditions

Healthy

Keywords

Analysis of plasma concentration of nalbuphine

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetic parameter eq Cmax, AUC, Cl, T1/2

  24 hours

Study Arms (1)

nalbuphine

EXPERIMENTAL

Drug: nalbuphine

Interventions

nalbuphine DRUG

oral dosage form, 66 mg, single dose

nalbuphine

Eligibility Criteria

• Age: 20 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Normal healthy adult subjects between 20-40 years of age.
• Body weight within 80-120% of ideal body weight. Ideal body weight = (height-80)0.7
• Acceptable medical history and physical examination including:
• Normal chest X-ray and ECG results within six months prior to Period I dosing.
• No particular clinical significance in general disease history within two months prior to Period I dosing.
• Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to Period I dosing, which includes:
• AST (SGOT)
• ALT (SGPT)
• Gama-GT
• alkaline phosphatase
• total bilirubin
• albumin
• glucose
• BUN
• uric acid

You may not qualify if:

• Recent history of drug or alcohol addiction or abuse.
• A clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
• History of allergic response(s) to nalbuphine or related drugs.
• History of clinically significant allergies including drug allergies or allergic bronchial asthma.
• Evidence of chronic or acute infectious diseases.
• Any clinically significant illness or surgery during the four weeks prior to Period I dosing (as determined by the clinical investigator).
• Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.
• Receiving any investigational drug within one month prior to Period I dosing.
• Taking any prescription medication or any nonprescription medication within two weeks prior to Period I doing.
• Donating greater than 150 ml of blood within two months prior to Period I dosing or donating plasma (e.g., plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
• Consumption of caffeine, xanthine-containing products (i.e., coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol at least 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.
• Any other medical reason as determined by the clinical investigator.
• Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.

Sponsors & Collaborators

• Tri-Service General Hospital: lead

Study Sites (1)

Tri-Service General Hospitial

Taipei, 11490, Taiwan

RECRUITING

MeSH Terms

Interventions

Nalbuphine

Intervention Hierarchy (Ancestors)

Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: June 17, 2009
• First Posted: June 18, 2009
• Study Start: September 1, 2008
• Primary Completion: November 1, 2009
• Last Updated: June 19, 2009

Record last verified: 2009-06

Locations

TW (1)